Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incyte Corp (NQ: INCY ) 67.63 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Incyte Corp < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Assessing Incyte: Insights From 11 Financial Analysts October 01, 2024 Via Benzinga Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate September 30, 2024 Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... Via Benzinga Exposures Product Safety Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress September 25, 2024 From Incyte Via Business Wire Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets September 18, 2024 Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) September 03, 2024 Via Benzinga Analyst Expectations For Incyte's Future August 15, 2024 Via Benzinga Analyst Ratings For Incyte July 26, 2024 Via Benzinga Looking for growth without the hefty price tag? Consider NASDAQ:INCY. July 22, 2024 INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably. Via Chartmill Wall Street Lower Ahead Of Interest Rate Move September 18, 2024 Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today. Via Talk Markets Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers September 16, 2024 Intel kept running late on yet another big deal. Via Investor's Business Daily Topics Stocks Exposures US Equities Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer September 14, 2024 From Incyte Via Business Wire Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium September 14, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 09, 2024 From Incyte Via Business Wire Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 August 21, 2024 From Incyte Via Business Wire Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study August 16, 2024 Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free... Via Benzinga Exposures Product Safety Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma August 15, 2024 From Incyte Via Business Wire FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication August 15, 2024 The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... Via Benzinga Exposures Product Safety Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) August 14, 2024 From Incyte and Syndax Pharmaceuticals Via Business Wire Incyte to Present at Upcoming Investor Conferences August 13, 2024 From Incyte Via Business Wire Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 07, 2024 From Incyte Via Business Wire After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial July 31, 2024 MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. Via Benzinga Topics Death Exposures Death Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance July 30, 2024 Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... Via Benzinga Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs July 30, 2024 From Incyte Via Business Wire NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. July 10, 2024 INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. Via Chartmill S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? July 09, 2024 The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s... Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Incyte to Report Second Quarter Financial Results July 09, 2024 From Incyte Via Business Wire The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 July 09, 2024 The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs. Via InvestorPlace 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 08, 2024 From Incyte Via Business Wire 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.